Skip to main content
    T

    TriSalus Life Sciences Inc. (TLSI)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $3.90
    -0.10 (-2.50%)

    Market Cap: $240.14M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    36%(4/11)
    Avg Surprise
    -38.23%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.15 - $-0.09
    5 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.10-24.9%
    60d ago$-0.10-24.9%
    30d ago$-0.13-2.4%
    7d ago$-0.12-3.2%
    Current$-0.13
    Revenue Consensus
    $14M
    Range$13M - $15M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.11
    Range$0.05 - $0.17
    5 analysts
    Revenue Consensus
    $18M
    Range$14M - $21M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.11---
    Sep 26EST
    		-$-0.13---
    Jun 26
    Reported Aug 6
    		$-0.16$-0.15-6.67%Miss+30.4%
    Mar 26
    Reported May 12
    		$0.03N/A+118.38%Beat+108.9%
    Dec 25
    Reported Mar 5
    		$-0.05N/A+61.54%Beat+87.5%
    Sep 25
    Reported Nov 13
    		$-0.87$-0.16-443.75%Miss-117.5%
    Jun 25
    Reported Aug 12
    		$-0.23$-0.22-4.55%Miss-9.5%
    Mar 25
    Reported May 15
    		$-0.33$-0.20-65.00%Miss+45.0%
    Dec 24
    Reported Mar 27
    		$-0.40$-0.35-14.29%Miss+74.4%
    Sep 24
    Reported Nov 14
    		$-0.40$-0.36-11.11%Miss-202.1%
    Jun 24
    Reported Aug 14
    		$-0.21N/A+54.35%Beat-70.3%
    Mar 24
    Reported May 15
    		$-0.60$-0.72+16.67%Beat-998.9%
    Dec 23
    Reported Mar 12
    		$-1.56$-0.69-126.09%Miss-15500.0%
    Sep 23
    Reported Nov 14
    		$-0.13N/AN/ABeat-762.0%
    Jun 23
    Reported Aug 30
    		$-0.12N/AN/ABeat-254.1%
    Mar 23
    Reported Jun 29
    		$-0.05N/AN/ABeat-160.7%
    Dec 22
    Reported Mar 30
    		$-0.01$0.00N/AMiss-111.1%
    Sep 22
    Reported Nov 10
    		$0.02$0.00N/ABeat-66.7%
    Jun 22
    Reported Aug 10
    		$0.08$0.00N/ABeat+700.0%
    Mar 22
    Reported May 11
    		$0.09$0.00N/ABeat+1000.0%
    Dec 21
    Reported Mar 2
    		$0.09$0.00N/ABeat-
    Sep 21
    Reported Dec 13
    		$0.06$0.00N/ABeat-
    Jun 21
    Reported Aug 16
    		$0.01$0.00N/ABeat-
    Mar 21
    Reported Jun 28
    		$-0.01$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.71EV/EBITDAN/A
    Price/FCF-9.77xFCF Yield-10.24%
    Profitability
    Profit Margin-62.60%Operating Margin-86.00%
    ROE-496.20%ROIC-58.89%
    Financial Health
    Debt/Equity5.05xInterest Coverage-4.00x
    Current Ratio5.35xQuick Ratio4.97x
    Trading Statistics
    Beta0.47Avg Volume472.51K
    52-Week High$7.9552-Week Low$2.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.16
    SMA 20$4.42
    SMA 50$4.83
    SMA 200$4.55
    EMA 10$4.16
    EMA 20$4.34
    EMA 50$4.54
    EMA 200$4.62

    MACD

    Line: -0.22Signal: -0.18Hist: -0.04

    ADX

    ADX: 9.2+DI: 18.2-DI: 22.9

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down100.0
    PSAR$4.85

    Bollinger Bands

    Upper Band$5.15
    Lower Band$3.69
    %B Position3323%(Upper)
    Band Width0.15

    RSI (14-Day)

    Neutral
    31.8

    Momentum Oscillators

    Stoch %K9.5
    Stoch %D8.4
    Williams %R-87.8
    ROC (10d)-9.5%
    Momentum-0.41
    CCI (20d)-108.5
    MFI (14d)34.1

    Volatility Measures

    ATR (14d)$0.31(7.8%)
    StdDev (20d)0.37
    Hist Vol48.9%(High)

    Volume Flow

    VWAP$3.90
    OBV4.4M
    AD Line788.4K
    CMF (20d)-0.373

    Volume Metrics

    Avg Vol (20d)503.8K
    Vol Ratio0.4x(Low)
    VWMA (20d)$4.71

    Pivot Points

    R3$4.28
    R2$4.20
    R1$4.10
    Pivot Point$4.02
    S1$3.92
    S2$3.84
    S3$3.74

    Advanced Oscillators

    TSI-27.06
    Ultimate Osc43.4
    KST-157.20

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$11.41M$8.90M$13.21M$11.57M$11.21M$9.17M$8.26M$7.35M$7.36M$6.46M$5.72M$5.19M
    Cost of Revenue$1.51M$1.23M$1.76M$1.91M$1.80M$1.50M$1.22M$1.00M$912,000$971,000$582,000$589,000
    Gross Profit$9.90M$7.67M$11.44M$9.66M$9.41M$7.67M$7.04M$6.34M$6.45M$5.49M$5.14M$4.60M
    Operating Expenses$19.71M$16.08M$14.71M$18.67M$16.74M$15.00M$14.63M$15.08M$14.63M$17.16M$19.44M$23.22M
    R&D$3.14M$3.22M$2.57M$5.18M$3.67M$3.02M$2.96M$4.22M$4.67M$5.84M$7.80M$9.51M
    SG&A$5.16M$5.45M$4.17M$6.66M$5.91M$5.25M$4.66M$4.73M$3.96M$4.63M$6.04M$9.03M
    Operating Income$-9,813,000$-8,411,000$-3,271,000$-9,014,000$-7,332,000$-7,329,000$-7,580,000$-8,739,000$-8,174,000$-11,672,000$-14,304,000$-18,616,000
    Interest Income$457,000$164,000$177,000$170,000$134,000$74,000$57,000$158,000$97,000$92,000$244,000$116,000
    Interest Expense$1.49M$1.44M$1.45M$1.46M$1.42M$1.21M$1.07M$1.14M$877,000$3,000$3,000$4,000
    Income Before Tax$-9,183,000$1.54M$-9,753,000$-10,806,000$-8,291,000$-10,370,000$-10,109,000$-2,402,000$-4,325,000$-13,203,000$-35,695,000$-1,425,000
    Income Tax Expense$4,000$4,000$0$5,000$-3,000$5,000$-1,000$-3,000$7,000$3,000$1,000$0
    Net Income$-9,187,000$1.54M$-9,753,000$-10,811,000$-8,288,000$-10,375,000$-10,108,000$-2,399,000$-4,332,000$-13,206,000$-35,696,000$-1,425,000
    EBITDA$-7,678,000$3.25M$-8,070,000$-9,662,000$-6,580,000$-8,828,000$-8,727,000$-1,220,000$-2,933,000$-13,117,000$-35,872,000$-1,251,000
    EBIT$-8,150,000$2.81M$-8,478,000$-9,516,000$-7,002,000$-9,235,000$-9,098,000$-1,418,000$-3,545,000$-13,292,000$-35,936,000$-1,537,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TLSI

    News

    Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call

    TriSalus Life Sciences reported strong Q2 2026 revenue of $11.4 million, showing sequential and year-over-year growth...

    Benzinga•10/12/26•Bullish

    296 shares sold for taxes: TriSalus Life Sciences (TLSI) research chief's sale was not discretionary.

    Bryan F. Cox, Chief of Research at TriSalus Life Sciences (TLSI), sold 296 common shares on October 5, 2026, at $4.39 per share. This transaction was not a discretionary sale but was conducted to cover tax withholding...

    Stock Titan•10/8/26•Neutral

    TriSalus Life Sciences (TLSI) regulatory chief sells 316 shares to cover stock-vesting taxes

    Jennifer Stevens, Chief Regulatory Officer at TriSalus Life Sciences (TLSI), sold 316 common shares at $4.39 each on October 5...

    Stock Titan•10/7/26•Neutral

    TLSI Options Chain — NASDAQ:TLSI

    This page provides the options chain for TriSalus Life Sciences, Inc. (TLSI) on the Nasdaq Stock Market. It allows users to view available call and put contracts, track market movements...

    TradingView•10/2/26•Neutral

    FDA Clears TriNav Advance for Expanded Liver Embolization Access

    The FDA has granted 510(k) clearance to TriSalus Life Sciences for its TriNav Advance device, designed to enhance tumor penetration during liver embolization procedures. This catheter-based system extends the company's...

    CancerNetwork•9/25/26•Bullish

    TLSI Valuation and Fair Value

    P/E
    -3.7x
    P/FCF
    -9.8x
    P/B
    34.7x
    See GNG's fair value

    TLSI Profitability: Margins, ROIC and FCF

    Gross margin
    85.8%
    Operating margin
    -86.0%
    Net margin
    -62.6%
    ROIC
    -58.9%
    ROE
    -496.2%
    FCF margin
    -51.6%
    FCF yield
    -10.2%

    TLSI Competitors

    CompanyTicker
    Profound Medical CorpPROF
    Fate Therapeutics IncFATE
    Rocket Pharmaceuticals IncRCKT
    Q32 Bio IncQTTB
    X4 Pharmaceuticals IncXFOR
    Utah Medical Products IncUTMD
    Lifecore Biomedical Inc.LFCR
    Immuneering CorpIMRX

    Sector: Healthcare

    TLSI Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    1
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    TLSI Bull Case vs Bear Case

    Bear case

    • TLSI has a -62.6% net profit margin.
    • TLSI beat EPS estimates in 25.0% of its last 8 reported quarters.
    • TLSI has a debt-to-equity ratio of 5.0x.

    TLSI Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -45.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.13
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About TLSI

    Does TLSI pay dividends?

    TriSalus Life Sciences Inc. (TLSI) does not currently pay a regular dividend.

    What is TLSI's market cap?

    TriSalus Life Sciences Inc. (TLSI) has a market capitalization of $240.14M with a current stock price of $3.90.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In